Transtek(SZ:300562) Zheng Quan Zhi Xing·2025-06-25 17:22Core Viewpoint - The announcement details the first exercise period of the 2024 stock option incentive plan for Guangdong Loxin Medical Electronics Co., Ltd, highlighting the conditions for exercising stock options and the implications for the company's financials and stock structure [2][6][9]. Summary by Sections Exercise Conditions - The first exercise period's conditions have been met, allowing 33 individuals to exercise their stock options at an adjusted price of 8.73 CNY per share [2][3]. - The exercise conditions include no adverse audit reports, no regulatory penalties for the participants, and the achievement of specific performance targets [3][4]. Performance Targets - The performance targets for the first exercise period require the company to achieve a net profit of 50 million CNY in 2024, with subsequent targets set for 2025 [4][6]. - The company’s performance will be audited, and the results will determine the eligibility for exercising stock options [3][6]. Exercise Arrangement - The exercise period is set from June 27, 2025, to June 26, 2026, with a total of 82,250 stock options available for exercise [6][8]. - The eligible participants include one director and 32 core technical/business personnel, with specific allocations of stock options [6][8]. Financial Impact - The exercise of stock options will increase the company's total share capital by 82,250 shares, with a minimal impact on earnings per share and return on equity [8][9]. - The funds raised from the exercise will be used to supplement the company's working capital, and the personal income tax for the participants will be withheld by the company [7][8]. Compliance and Reporting - The company has engaged Guotai Junan Securities Co., Ltd. to facilitate the exercise process, ensuring compliance with relevant regulations [7][8]. - Future reports will disclose changes in stock option participants, adjustments to important parameters, and the status of stock option exercises [9].